Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.

Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig S, Vallet S, Pozzi S, Patel K, Unitt C, Squires M, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje N.

Clin Cancer Res. 2011 May 15;17(10):3259-71. doi: 10.1158/1078-0432.CCR-10-3012. Epub 2011 Mar 23.

PMID:
21430070
[PubMed - indexed for MEDLINE]
Free Article
2.

AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.

Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M, Mahadevan D.

Int J Cancer. 2012 Jun 15;130(12):2997-3005. doi: 10.1002/ijc.26324. Epub 2011 Nov 19.

PMID:
21796626
[PubMed - indexed for MEDLINE]
3.

Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.

Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, Wallis N.

Cell Cycle. 2009 Jun 15;8(12):1921-9. Epub 2009 Jun 15.

PMID:
19440047
[PubMed - indexed for MEDLINE]
Free Article
4.

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.

Dawson MA, Curry JE, Barber K, Beer PA, Graham B, Lyons JF, Richardson CJ, Scott MA, Smyth T, Squires MS, Thompson NT, Green AR, Wallis NG.

Br J Haematol. 2010 Jul;150(1):46-57. doi: 10.1111/j.1365-2141.2010.08175.x. Epub 2010 May 7.

PMID:
20507304
[PubMed - indexed for MEDLINE]
5.

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.

Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Rees DC, Reule M, Tisi D, Williams G, Vinković M, Wyatt PG.

J Med Chem. 2009 Jan 22;52(2):379-88. doi: 10.1021/jm800984v.

PMID:
19143567
[PubMed - indexed for MEDLINE]
6.

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.

Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, Takeuchi M, Yao H, Reule M, Smyth T, Lyons JF, Thompson NT, Ashihara E, Ottmann OG, Maekawa T.

Blood. 2010 Sep 23;116(12):2089-95. doi: 10.1182/blood-2009-03-211466. Epub 2010 Jun 14.

PMID:
20548094
[PubMed - indexed for MEDLINE]
Free Article
7.

Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.

Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN Jr, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK.

Clin Cancer Res. 2008 Sep 1;14(17):5437-46. doi: 10.1158/1078-0432.CCR-07-4922.

PMID:
18765535
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, Sparks RB, Arvanitis A, Rogers JD, Combs AP, Vaddi K, Solomon KA, Scherle PA, Newton R, Fridman JS.

Neoplasia. 2010 Jan;12(1):28-38.

PMID:
20072651
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.

Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Braig M, Wege H, Moll J, Lohse AW, Brummendorf TH.

Neoplasia. 2009 Sep;11(9):934-44.

PMID:
19724687
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.

Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, Miki S, Kawanishi N, Ohkubo M, Kotani H, Iwasawa Y.

Mol Cancer Ther. 2010 Jan;9(1):157-66. doi: 10.1158/1535-7163.MCT-09-0609. Epub 2010 Jan 6.

PMID:
20053775
[PubMed - indexed for MEDLINE]
Free Article
11.

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC.

Blood. 2010 Jun 24;115(25):5202-13. doi: 10.1182/blood-2009-12-259523. Epub 2010 Apr 9.

PMID:
20382844
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.

Wang X, Sinn AL, Pollok K, Sandusky G, Zhang S, Chen L, Liang J, Crean CD, Suvannasankha A, Abonour R, Sidor C, Bray MR, Farag SS.

Br J Haematol. 2010 Aug;150(3):313-25. doi: 10.1111/j.1365-2141.2010.08248.x. Epub 2010 Jun 15.

PMID:
20560971
[PubMed - indexed for MEDLINE]
13.

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Lai R, Reiman T.

Br J Haematol. 2008 Feb;140(3):295-302. Epub 2007 Dec 10.

PMID:
18076711
[PubMed - indexed for MEDLINE]
14.

Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.

Podesta JE, Sugar R, Squires M, Linardopoulos S, Pearson AD, Moore AS.

Leuk Res. 2011 Sep;35(9):1273-5. doi: 10.1016/j.leukres.2011.05.022. Epub 2011 Jun 12.

PMID:
21665275
[PubMed - indexed for MEDLINE]
15.

Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.

Jayanthan A, Cooper TM, Hoeksema KA, Lotfi S, Woldum E, Lewis VA, Narendran A.

Leuk Lymphoma. 2013 Jul;54(7):1505-16. doi: 10.3109/10428194.2012.752079. Epub 2012 Dec 29.

PMID:
23176524
[PubMed - indexed for MEDLINE]
16.

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.

Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, Ecsedy J, Giles FJ, Carew JS.

Int J Cancer. 2012 Dec 1;131(11):2693-703. doi: 10.1002/ijc.27579. Epub 2012 Jun 28.

PMID:
22488249
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.

Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH.

J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. doi: 10.1124/jpet.112.197087. Epub 2012 Aug 30.

PMID:
22935731
[PubMed - indexed for MEDLINE]
Free Article
18.

GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.

Hardwicke MA, Oleykowski CA, Plant R, Wang J, Liao Q, Moss K, Newlander K, Adams JL, Dhanak D, Yang J, Lai Z, Sutton D, Patrick D.

Mol Cancer Ther. 2009 Jul;8(7):1808-17. doi: 10.1158/1535-7163.MCT-09-0041. Epub 2009 Jun 30.

PMID:
19567821
[PubMed - indexed for MEDLINE]
Free Article
19.

Identification of an Aurora kinase inhibitor specific for the Aurora B isoform.

Xie H, Lee MH, Zhu F, Reddy K, Peng C, Li Y, Lim do Y, Kim DJ, Li X, Kang S, Li H, Ma W, Lubet RA, Ding J, Bode AM, Dong Z.

Cancer Res. 2013 Jan 15;73(2):716-24. doi: 10.1158/0008-5472.CAN-12-2784. Epub 2012 Nov 1.

PMID:
23117881
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.

Fiskus W, Hembruff SL, Rao R, Sharma P, Balusu R, Venkannagari S, Smith JE, Peth K, Peiper SC, Bhalla KN.

Breast Cancer Res Treat. 2012 Sep;135(2):433-44. doi: 10.1007/s10549-012-2171-9. Epub 2012 Jul 24.

PMID:
22825030
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk